Tessera Therapeutics Raises Over $300M in Series C Financing
Summary
Led by Geoffrey von Maltzahn, Ph.D., Co-Founder, Chief Executive Officer, and Board Director, Tessera Therapeutics provides gene writing technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. Tessera’s gene writer tools are based on nature’s genome architects, Mobile Genetic Elements (MGEs)—the most abundant class of genes across the tree of life, representing approximately half of the human genome. The company has evaluated tens of thousands of natural and synthetic MGEs to create candidates with the ability to write therapeutic messages into the human genome. Its research engine further optimizes the discovered candidates for efficiency, specificity, and fidelity—essentially compressing eons of evolution into a few months. Noubar Afeyan, Ph.D., is Co-Founder and Chairman of Tessera Therapeutics and Founder and CEO of Flagship Pioneering.
Funding
Review available funding amount, funding date, investors, and linked company information related to Tessera Therapeutics Raises Over $300M in Series C Financing in the interactive ISVWorld profile.